HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01157351

Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia

Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Bullhead City and 55 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study clarity

Study information

Study start dateMay 2010
Recruitment status
Completed
Enrollment listed in the registry
450
Sponsor
Janssen Scientific Affairs, LLC
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT01157351
Official title
Show the full official title

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bullhead City, United States · Tuscon, United States · Little Rock, United States

53 more locations
  • Anaheim, United States
  • Escondido, United States
  • Glendale, United States
  • Imperial, United States
  • Long Beach, United States
  • National City, United States
  • Oakland, United States
  • Oceanside, United States
  • Pico Rivera, United States
  • Riverside, United States
  • San Bernadino, United States
  • San Diego, United States
  • San Fran Cisco, United States
  • New Britain, United States
  • New London, United States
  • Leesburg, United States
  • Miami, United States
  • Miami Gardens, United States
  • Pensacola, United States
  • Tamarac, United States
  • Tampa, United States
  • Honolulu, United States
  • Chicago, United States
  • Hoffman Estates, United States
  • Naperville, United States
  • Springfield, United States
  • Wichita, United States
  • Witchita, United States
  • New Orleans, United States
  • Shreveport, United States
  • Flowood, United States
  • Kansas City, United States
  • Omaha, United States
  • Las Vegas, United States
  • Paramus, United States
  • Willingboro, United States
  • Buffalo, United States
  • New York, United States
  • Cleveland, United States
  • Middleburg Heights, United States
  • Willoughby, United States
  • Oklahoma City, United States
  • Allentown, United States
  • Philadelphia, United States
  • Charleston, United States
  • Nashville, United States
  • DeSoto, United States
  • Irving, United States
  • San Antonio, United States
  • Wharton, United States
  • Bothell, United States
  • Spokane, United States
  • Rio Piedras, Puerto Rico
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen Scientific Affairs, LLC.

Did this study involve medication?

Yes. The study involved medication, including paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate and olanzapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me